IOVAIovance Biotherapeutics, Inc.Signing up patients
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Metastatic Melanoma · Unresectable Melanoma · Melanoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 670 (planned)
- Started
- Mar 30, 2023
- Main results expected
- Mar 1, 2028
- Fully finished
- Mar 1, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response Rate and Progression Free Survival
Measured over: 5 years total duration
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05727904 · record last updated 2026-09-24 · checked 2026-11-09 15:47 UTC